Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura

Recruiting now

Conditions studied: Thrombotic Thrombocytopenic Purpura, Acquired

In brief

Data about efficacy and safety of daratumumab in iTTP refractory or intolerant to standard immunosuppressive treatments are scarce. Therefore, the investigators aim at collecting evidence on a larger number of patients through a collaborative, international study.

Key facts

Study ID

NCT07513948

Run by

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

People needed

40

Starts

2025-10-01

Expected to finish

2026-08-01

Last updated by the study team

2026-04-14

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients with a confirmed diagnosis of iTTP (i.e., ADAMTS13 activity <10% with anti-ADAMTS13 antibodies detected);
• aged ≥ 18 years;
• male and female patients;
• treated with daratumumab for iTTP.

You may not qualify if…

• patients unwilling or unable to provide their informed consent;
• follow-up < 6 months after daratumumab administration.

Where it is running

• Angelo Bianchi Bonomi Hemophilia and Thrombosis Center — Milan, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.